Clinical trials: Stage III Lung Non-Small Cell Cancer AJCC v7
Non-Small Cell Lung Cancer (Stage III)
Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC
This is a prospective, open, multicenter, Phase II single-arm clinical study. In subjects with an initial stage of stage III-N3 non-small cell lung cancer (NSCLC) that was negative for sensitive gene mutations and had not…
- Trial name
- NCT06908733
- Testing
- 3-4 cycles of Tislelizumab combined with platinum-based chemotherapy, evaluated by MDT and assigned to treatment strategies based on eligibility and patient preference.
- Volunteers
- 30 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Lung Cancer
Stereotactic Radiosurgery in Treating Patients Undergoing Chemotherapy and Radiation Therapy For Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00945451
- Testing
- CK
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Centre Antoine Lacassagne
Non Small Cell Lung Cancer Metastatic, Lung Diseases
PALACE: Cemiplimab Trial According to ctDNA Levels
This is an open-label, non-randomised, phase II, multicenter clinical trial. 63 stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th…
- Conditions
- Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell Lung Cancer
- Trial name
- PALACE (NCT06917573)
- Testing
- Cemiplimab, Carboplatin, Paclitaxel
- Where
- 20 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Fundación GECP
Non-Small-Cell Lung Cancer
A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC
The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without chemotherapy in the treatment of unresectable stage III non-small cell lung cancer
- Trial name
- NCT04580498
- Testing
- SHR-1701+Paclitaxel+carboplatin, SHR-1701
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-small Cell Lung Cancer Stage III
Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer
Concurrent chemoradiotherapy without disease progression followed by consolidation durvalumab is standard of care for unresectable, stage III non-small-cell lung cancer (NSCLC) (the 'PACIFIC regimen').
- Trial name
- NCT05557552
- Testing
- standar thoracic RT dose, decreased thoracic RT dose
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Ruijin Hospital
NSCLC, Stage IIIA, NSCLC (non-small Cell Lung Cancer)
Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer
To investigate the efficacy and safety of neoadjuvant treatment with Tislelizumab combined with chemotherapy for initially unresectable N2/III non-small cell lung cancer.
- Trial name
- NCT06614231
- Testing
- Tislelizumab Combined With Chemotherapy
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Non-Small-Cell Lung Cancer
Reduced-Dose vs Standard-Dose Thoracic Radiotherapy After Induction Chemoimmunotherapy in Older or Frail Stage III NSCLC
This is a multicenter, open-label, randomized phase III study in older or frail adults with unresectable stage III non-small cell lung cancer (NSCLC) who are considered unsuitable for concurrent chemoradiotherapy.
- Trial name
- NCT07908745
- Testing
- Reduced-Dose Thoracic Radiotherapy, Standard-Dose Thoracic Radiotherapy
- Volunteers
- 276 people
- Sponsor
- Ruijin Hospital
NSCLC
Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer
Stratification of postoperative ctDNA status can effectively assess the risk of recurrence in patients. In addition, the multi-node dynamic monitoring of ctDNA is more effective in predicting the recurrence risk of patients.
- Trial name
- MRDinS3LC (NCT06081777)
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking University Cancer Hospital & Institute
Lung Cancer Stage III, Mutation
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
This umbrella trial directed by next generation sequencing (NGS) includes patients with treatment-naive unresectable stage III non-small-cell lung cancer (NSCLC).
- Trial name
- NUMER (NCT06563999)
- Testing
- Sunvozertinib, Crizotinib, Pralsetinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Unresectable Locally Advanced Non-small Cell Lung Cancer
Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis
A prospective, single-center, phase II clinical study of adebrelimab combined with apatinib in the treatment of unresectable stage III NSCLC patients with grade ≤2 radiation pneumonitis after definitive chemoradiotherapy
- Trial name
- NCT06700421
- Testing
- Adebrelimab + Apatinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Wei Zhou
Locally-Advanced Non-Small Cell Lung Cancer, Radiotherapy
Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC
This is a single-center, prospective, open-label, single-arm phase I exploratory study designed to evaluate the safety and feasibility of a novel central immune-priming radiotherapy strategy in patients with unresectable stage…
- Trial name
- NCT07523464
- Testing
- Centrally Confined 8 Gy/1 Fraction Immune-Priming Radiotherapy to the Tumor Core Followed by Definitive Concurrent Chemoradiotherapy
- Volunteers
- 24 people
- Sponsor
- Anhui Provincial Hospital
Lung Cancer
Positron Emission Tomography Scan and CT Scan in Planning Radiation Therapy for Patients With Stage II or Stage III Non-Small Cell Lung Cancer
RATIONALE: Imaging procedures, such as positron emission tomography (PET) scan and CT scan, may help doctors plan radiation therapy for patients with non-small cell lung cancer.
- Trial name
- NCT00310219
- Testing
- computed tomography, positron emission tomography
- Where
- 4 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Radiation Therapy Oncology Group
Non-small Cell Lung Cancer Stage III
A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)
This study seeks to establish the recommended Phase 2 dose (RPTD) of veliparib in combination with concurrent paclitaxel/carboplatin-based chemoradiotherapy (CRT) and consolidation with paclitaxel/carboplatin-based chemotherapy…
- Trial name
- NCT02412371
- Testing
- Paclitaxel, Carboplatin, Veliparib
- Where
- 12 sites in United States
- Volunteers
- 48 people
- Sponsor
- AbbVie
Lung Cancer
Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898924
- Testing
- molecular diagnostic method, mutation analysis
- Volunteers
- 60 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Small Cell Lung Cancer Stage III
Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）
Evaluate the efficacy and safety of Anlotinib following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer
- Trial name
- ALTER-L029 (NCT03743129)
- Testing
- Anlotinib
- Where
- 4 sites in China
- Volunteers
- 90 people
- Sponsor
- Anhui Shi, MD
Lung Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Specialized radiation therapy delivers a high dose of radiation directly to the tumor which may kill more…
- Trial name
- NCT00004253
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 2 sites in United States
- Sponsor
- Baptist Health South Florida
Lung Cancer
Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET), (done before, during, and after chemotherapy) may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00227539
- Testing
- cisplatin, pemetrexed disodium, adjuvant therapy
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Washington
Unresectable Stage III Non-small-cell Lung Cancer
Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer
For unresectable stage III (8th TNM) non-small cell lung cancer, chemoradiotherpay plus immunotherapy is recommended by PACIFIC trial.
- Trial name
- NCT06591910
- Testing
- Chemoimmunotherapy, Surgery, Radiation
- Volunteers
- 50 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7
Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer
This phase I/II trial studies the best dose and side effects of anetumab ravtansine when given together with atezolizumab and how well they work in treating participants with non-small cell lung cancer that has spread to other…
- Conditions
- Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT03455556
- Testing
- Anetumab Ravtansine, Atezolizumab, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Non-Small Cell Lung Cancer
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
The rationale for this multicenter, phase II trial is to examine the impact of carboplatin/paclitaxel with bevacizumab in the preoperative treatment of patients with stage IB (> 4.0 cm), II, and select stage III NSCLC.
- Trial name
- NCT00960297
- Testing
- Carboplatin, Paclitaxel, Bevacizumab
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- SCRI Development Innovations, LLC